Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Herz
Erschienen in: Herz 4/2013

01.06.2013 | e-Herz: Original article

Increased H-FABP concentrations in nonalcoholic fatty liver disease

Possible marker for subclinical myocardial damage and subclinical atherosclerosis

verfasst von: Ö. Başar, M.D., E. Akbal, S. Köklü, Y. Tuna, E. Koçak, N. Başar, D. Tok, H. Erbiş, M. Şenes

Erschienen in: Herz | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Aim

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder which is reported as the hepatic manifestation of metabolic syndrome with an increased risk of cardiovascular events. Patients with NAFLD are also at risk of future cardiac events independently of metabolic syndrome. The aim of this study was to examine serum concentrations of heart type fatty acid binding protein (H-FABP) in NAFLD and to investigate its correlations with metabolic parameters and subclinical atherosclerosis.

Patients and methods

A total of 34 patients with NAFLD and 35 healthy subjects were enrolled in the study. NAFLD patients had elevated liver enzymes and steatosis graded on ultrasonography. Healthy subjects had normal liver enzymes and no steatosis on ultrasonography. H-FABP levels were measured using an enzyme linked immunosorbent assay (ELISA) method and correlations with metabolic parameters and subclinical atherosclerosis were examined. Subclinical atherosclerosis was determined with carotid artery intima–media thickness (CIMT) which was measured by high resolution B mode ultrasonography.

Results

H-FABP levels were elevated in patients with NAFLD (16.3 ± 4.0 ng/ml) when compared with healthy controls (13.8 ± 2.1 ng/ml; p  < 0.001). NAFLD patients had significantly higher CIMT than the controls had (0.64 ± 0.17 mm vs. 0.43 ± 0.14 mm, p = 0.009). The H-FABP concentrations were significantly positively correlated with body mass index (r = 0.255, p = 0.042), fasting blood glucose level (r = 0.300, p = 0.013), CIMT (r = 0.335, p = 0.043), and homeostasis model assessment-estimated insulin resistance (HOMA-IR; r = 0.156, p = 0.306). In multiple linear regression analysis, H-FABP levels were only independently associated with CIMT (p = 0.04)

Conclusion

Serum H-FABP concentrations increase in patients with NAFLD. Our results may not only suggest that H-FABP is a marker of subclinical myocardial damage in patients with NAFLD but also of subclinical atherosclerosis, independent of metabolic syndrome and cardiac risk factors.
Literatur
1.
Angulo P (2002) Medical progress: nonalcoholic fatty liver disease. N Engl J Med 346:1221–1231PubMedCrossRef
2.
Edmison J, McCullough AJ (2007) Pathogenesis of nonalcoholic steatohepatitis: human data. Clin Liver Dis 11:75–104PubMedCrossRef
3.
Marchesini G, Brizi M, Bianchi G, Tomassetti S et al (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844–1850PubMedCrossRef
4.
Polak JF, Pencina MJ, Pencina KM et al (2011) Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med 365:213–221PubMedCrossRef
5.
O’Leary DH, Polak JF, Kronmal RA et al (1999) Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 340:14–22CrossRef
6.
Salonen JT, Salonen R (1993) Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 87(suppl):II56–II65PubMed
7.
Chambless LE, Heiss G, Folsom AR et al (1997) Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am J Epidemiol 146:483–494PubMedCrossRef
8.
Salonen R, Salonen JT (1990) Progression of carotid atherosclerosis and its determinants: a population-based ultrasonography study. Atherosclerosis 81:33–40PubMedCrossRef
9.
Fournier NC, Richard MA (1990) Role of fatty acid-binding protein in cardiac fatty acid oxidation. Mol Cell Biochem 98:149–159PubMedCrossRef
10.
Pelsers MM, Hermens WT, Glatz JF (2005) Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta 352:15–35PubMedCrossRef
11.
Adams JE, Trent R, Rawles J (1993) Earliest electrocardiographic evidence of myocardial infarction: implications for thrombolytic treatment. Br Med J 307:409–413CrossRef
12.
Ishii J, Wang JH, Naruse H et al (1997) Serum concentrations of myoglobin vs. human heart-type cytoplasmic fatty acid-binding protein in early detection of acute myocardial infarction. Clin Chem 43:1372–1378PubMed
13.
Kleine AH, Glatz JFC, Nieuwenhoven FA van et al (1992) Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man. Mol Cell Biochem 116:155–162PubMedCrossRef
14.
Vuilleumier N, Righini M, Perrier A et al (2008) Correlation between cardiac biomarkers and right ventricular enlargement on chest CT in non massive pulmonary embolism. Thromb Res 21:617–624CrossRef
15.
Sugiura T, Takase H, Toriyama T et al (2005) Circulating levels of myocardial proteins predict future deterioration of congestive heart failure. J Card Fail 11:504–509PubMedCrossRef
16.
Nagahara D, Nakata T, Hashimoto A et al (2006) Early positive biomarker in relation to myocardial necrosis and impaired fatty acid metabolism in patients presenting with acute chest pain at an emergency room. Circ J 70:419–425PubMedCrossRef
17.
Arimoto T, Takeishi Y, Niizeki T et al (2007) Cardiac sympathetic denervation and ongoing myocardial damage for prognosis in early stages of heart failure. J Card Fail 13:34–41PubMedCrossRef
18.
Niizeki T, Takeishi Y, Takabatake N et al (2007) Circulating levels of heart-type fatty acid-binding protein in a general Japanese population: effects of age, gender, and physiologic characteristics. Circ J 71:1452–1457PubMedCrossRef
19.
Komamura K, Sasaki T, Hanatani A et al (2006) Heart-type fatty acid binding protein is a novel prognostic marker in patients with non-ischaemic dilated cardiomyopathy. Heart 92:615–628PubMedCrossRef
20.
Wunderlich MT, Hanhoff T, Goertler M et al (2005) Release of brain-type and heart type fatty acid-binding proteins in serum after acute ischaemic stroke. J Neurol 252:718–724PubMedCrossRef
21.
Renaud B, Ngako A (2007) Heart-type fatty acid-binding proteins (H-FABP): a reliable tool for initial risk stratification of pulmonary embolism? Eur Heart J 28:146–157PubMedCrossRef
22.
Oktay B, Akbal E, Firat H et al (2008) Evaluation of the relationship between heart type fatty acid binding protein levels and the risk of cardiac damage in patients with obstructive sleep apnea syndrome. Sleep Breath 12:223–228PubMedCrossRef
23.
Zimmermann-Ivol CG, Burkhard PR, Le Floch-Rohr J et al (2004) Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study. Mol Cell Proteomics 3:66–72PubMed
24.
Wada-Isoe K, Imamura K, Kitamaya M et al (2008) Serum heart-fatty acid binding protein levels in patients with Lewy body disease. J Neurol Sci 266:20–24PubMedCrossRef
25.
Akbal E, Özbek M, Güneş F et al (2009) Serum heart type fatty acid binding protein levels in metabolic syndrome. Endocrine 36:433–437PubMedCrossRef
26.
Karbek B, Özbek M, Bozkurt NC et al (2011) Heart-type fatty acid binding protein (H-FABP): relationship with arterial intima-media thickness and role as diagnostic marker for atherosclerosis in patients with impaired glucose metabolism. Cardiovasc Diabetol 2:10–37
27.
Hamaguchi M, Kojima T, Itoh Y et al (2007) The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 12:2708–2715CrossRef
28.
Bhatia LS, Curzen NP, Calder PC et al (2012) Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 33:1190–2000PubMedCrossRef
29.
Fraser A, Harris R, Sattar N et al (2007) Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women’s Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 27:2729–2735PubMedCrossRef
30.
Mottillo S, Filion KB, Genest J et al (2010) The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol 56:1113–1132PubMedCrossRef
31.
Lucero D, Zago V, Lopez GI et al (2011) Pro-inflammatory and atherogenic circulating factors in nonalcoholic fatty liver disease associated to metabolic syndrome. Clin Chim Acta 412:143–147PubMedCrossRef
32.
Wong CKL, Burgess MI, Pugh CJ et al (2011) Elevated liver fat in non alcoholic fatty liver disease is associated with impaired myocardial relaxation. J Diabetes 3:202
33.
Wong CK, Burgess MI, Irwin A et al (2010) Evidence of diastolic dysfunction in NAFLD: a study using tissue Doppler echocardiography. Diabetologia 53:495–496
34.
Seo JM, Park TH, Lee DY et al (2011) Subclinical myocardial dysfunction in metabolic syndrome patients without hypertension. J Cardiovasc Ultrasound 19:134–139PubMedCrossRef
35.
Dinh W, Lankisch M, Nickl W et al (2011) Metabolic syndrome with or without diabetes contributes to left ventricular diastolic dysfunction. Acta Cardiol 66:167–174PubMed
36.
Witteles RM, Fowler MB (2008) Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 51:93–102PubMedCrossRef
37.
Tanaka T, Hirota Y, Sohmiya K et al (1991) Nishimura S, Kawamura K. Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction. Clin Biochem 24:195–201PubMedCrossRef
38.
Glatz JF, Kleine AH, Nieuwenhoven FA van et al (1994) Fatty acid-binding protein as a plasma marker for the estimation of myocardial infarct size in humans. Br Heart J 71:135–140PubMedCrossRef
39.
Setsuta K, Seino Y, Ogawa T et al (2002) Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure. Am J Med 113:717–722PubMedCrossRef
40.
Arimoto T, Takeishi Y, Shiga R et al (2005) Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure. J Card Fail 11:56–60PubMedCrossRef
41.
Niizeki T, Takeishi Y, Arimoto T et al (2005) Risk stratification using a combination of heart-type fatty acid binding protein and brain natriuretic peptide in patients hospitalized for congestive heart failure. Circ J 69:922–927PubMedCrossRef
42.
Niizeki T, Takeishi Y, Arimoto T et al (2005). Serum heart-type fatty acid binding protein predicts cardiac events in elderly patients with chronic heart failure. J Cardiol 46:9–15PubMed
43.
Niizeki T, Takeishi Y, Arimoto T et al (2007) Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients. J Card Fail 13:120–127PubMedCrossRef
44.
Ohno K, Tsutamoto T, Ishikawa C et al (2004) Relationship between the transcardiac increase of plasma heart-type fatty acid-binding protein and left ventricular remodeling in patients with dilated cardiomyopathy J Am Coll Cardiol 3:1031–1134
45.
Morioka N, Shigematsu Y, Hamada M et al (2005) Circulating levels of heart-type fatty acid-binding protein and its relation to thallium-201 perfusion defects in patients with hypertrophic cardiomyopathy. Am J Cardiol 195:1334–1337CrossRef
46.
Lim TK, Lim E, Dwivedi G et al (2008) Normal value of carotid intima-media thickness—a surrogate marker of atherosclerosis: quantitative assessment by B-mode carotid ultrasound. J Am Soc Echocardiogr 21:112–116PubMedCrossRef
47.
Raitakari OT, Juonala M, Kähönen M et al (2003) Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 290:2277–2283PubMedCrossRef
48.
Tzou WS, Douglas PS, Srinivasan SR et al (2005) Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogalusa Heart Study. J Am Coll Cardiol 46:457–463PubMedCrossRef
49.
Skilton MR, Moulin P, Serusclat A et al (2007) A comparison of the NCEPATP III, IDF and AHA/NHLBI metabolic syndrome definitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at risk of CVD: evidence for sex-specific differences. Atherosclerosis 190:416–422PubMedCrossRef
50.
Czernichow S, Bertrais S, Blacher J et al (2005) Metabolic syndrome in relation to structure and function of large arteries: a predominant effect of blood pressure. A report from the SU.VI.MAX. Vascular Study. Am J Hypertens 18:1154–1160PubMedCrossRef
51.
Bertoni AG, Wong ND, Shea S et al (2007) Insulin resistance, metabolic syndrome, and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 30:2951–2956PubMedCrossRef
52.
Marchesini G, Bugianesi E, Forlani G et al (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917–923PubMedCrossRef
53.
Rector RS, Thyfault JP, Wei Y et al (2008) Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 14:185–192PubMedCrossRef
54.
Kim JH, Kim SY, Jung ES et al (2011) Carotid intima-media thickness is increased not only in non-alcoholic fatty liver disease patients but also in alcoholic Fatty liver patients. Digestion 84:149–155PubMedCrossRef
55.
Wong VW, Wong GL, Yip GW et al (2011) Coronary artery disease and cardiovascular outcomes in patients with nonalcoholic fatty liver disease. Gut 60:1721–1727PubMedCrossRef
56.
Sun L, Lu SZ (2011) Association between nonalcoholic fatty liver disease and coronary artery disease severity. Chin Med J (Engl) 124:867–872
57.
Mohammadi A, Bazazi A, Ghasemi-Rad M et al (2011) Evaluation of atherosclerotic findings in patients with nonalcoholic fatty liver disease. Int J Gen Med 4:717–722PubMedCrossRef
58.
Kim D, Choi SY, Park EH et al (2012) Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 56:605–613PubMedCrossRef
59.
Kang MK, Yoon H, Seon H et al (2011) Association between nonalcoholic fatty liver disease and subclinical coronary atherosclerosis determined by MDCT. Hepatology 54:1115A–1116ACrossRef
Metadaten
Titel
Increased H-FABP concentrations in nonalcoholic fatty liver disease
Possible marker for subclinical myocardial damage and subclinical atherosclerosis
verfasst von
Ö. Başar, M.D.
E. Akbal
S. Köklü
Y. Tuna
E. Koçak
N. Başar
D. Tok
H. Erbiş
M. Şenes
Publikationsdatum
01.06.2013
Verlag
Urban and Vogel
Erschienen in
Herz / Ausgabe 4/2013
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-012-3714-x

Weitere Artikel der Ausgabe 4/2013

Herz 4/2013 Zur Ausgabe

e-Herz: Case study

Torsade de pointes

Schwerpunkt

Diagnostik und Therapie der chronischen Myokardischämie

e-Herz: Case study

Fungal endocarditis of a bioprosthetic aortic valve

Editorial

Diagnostik und Therapie der chronischen Myokardischämie

Schwerpunkt

Diagnostik und Therapie der chronischen Myokardischämie

Image of the month

First septal artery originating from the left main coronary artery

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen